Unibest
← Back to patent-cliff list

Florzolotau

Tier C — Watch / trade

Florzolotau

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:TAU

Indications (approved):Alzheimer's disease, Mild cognitive impairment, Cognitive impairment, 神经变性, Diagnostic agent, 进行性核上性麻痹

Regional status

US
Phase II
2022-03-22
EU
-
China
Phase III
2022-01-21
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield /
APN-1607-00139856-50-3APN-1607-0023054-95-3APN-1607-0031565798-10-8APN-1607-0041565797-70-7APN-1607-0051565797-71-8APN-1607-0061565797-72-9APN-1607-0071565797-73-0APN-1607-0081565797-40-1APN-1607-009—APN-1607-010—API · Florzolotau
CodeCAS No.Intermediate
APN-1607-00139856-50-3Available5-bromo-2-nitropyridine
APN-1607-0023054-95-33,3-diethoxyprop-1-ene
APN-1607-0031565798-10-8(E)-3-(6-nitropyridin-3-yl)acrylaldehyde
APN-1607-0041565797-70-7diethyl ((6-methoxybenzo[d]thiazol-2-yl)methyl)phosphonate
APN-1607-0051565797-71-86-methoxy-2-((1E,3E)-4-(6-nitropyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazole
APN-1607-0061565797-72-95-((1E,3E)-4-(6-methoxybenzo[d]thiazol-2-yl)buta-1,3-dien-1-yl)pyridin-2-amine
APN-1607-0071565797-73-05-((1E,3E)-4-(6-methoxybenzo[d]thiazol-2-yl)buta-1,3-dien-1-yl)-N-methylpyridin-2-amine
APN-1607-0081565797-40-12-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-ol
APN-1607-009-2-((tert-butyldimethylsilyl)oxy)-3-(fluoro-18F)propan-1-ol
APN-1607-010-5-((1E,3E)-4-(6-(2-((tert-butyldimethylsilyl)oxy)-3-(fluoro-18F)propoxy)benzo[d]thiazol-2-yl)buta-1,3-dien-1-yl)-N-methylpyridin-2-amine

Frequently asked questions

What are the approved indications of Florzolotau?

Approved indications include: Alzheimer's disease, Mild cognitive impairment, Cognitive impairment, 神经变性, Diagnostic agent, 进行性核上性麻痹.

When does the Florzolotau patent expire?

No public expiry year is available for Florzolotau yet; this page updates once verified.

How many synthesis routes are recorded for Florzolotau?

1 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Florzolotau intermediates?

1 intermediate CAS of Florzolotau are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Florzolotau intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-05